Why this moment matters for hydrocephalus research

There are moments in a company's journey that feel especially meaningful. This is one of them.

At the American Association of Neurological Surgeons (AANS), 2026 AANS Annual Scientific Meeting our CEO and co-founder Simon Malpas PhD presented on investigational approaches to home intracranial pressure (ICP) monitoring and what it could mean for ongoing research in hydrocephalus. Hydrocephalus is a condition that does not stay still. Symptoms can change and fluctuate. Yet much of the current care model relies on visits to hospital and healthcare visits. Between these encounters, clinicians and families have limited quantitative information to help understand changes in symptoms. For patients and families this can mean feelings of uncertainty. It can mean waiting for answers and trying to interpret what changing symptoms might mean. At Kitea Health we are working toward something different.

Intracranial pressure plays a central role to understanding hydrocephalus. Traditionally, ICP measurement has been confined to in clinical settings and only in specific scenarios. This has led researchers and clinicians to explore new investigational approaches that enable ICP measurements to be captured more frequently outside healthcare visits. At Kitea, we are conducting studies of our investigational system designed to enable ICP measurement outside the clinic and inform the development and evaluation of future clinical workflows.

The AANS Annual Scientific Meeting brings together leading neurosurgeons and researchers from around the world. It is a place where ideas are shared and future directions in care are shaped. Being part of this discussion is meaningful for us. It is an opportunity to contribute what we have learned during our research and engage in broader scientific dialogue about management of neurological conditions. This presentation follows the completion of our clinical trials in Auckland New Zealand evaluating our investigational technology. These trials reflect the commitment of participating patients, families, clinicians and researchers who play a critical role in advancing this work.

Our focus remains simple.

Presenting at AANS represents an important milestone, but is not the end of the journey. It is one step of a longer effort explore novel technology and contribute to ongoing research focused on patient-centred care for people living with hydrocephalus.

Kitea’s technology is investigational and is not commercially available. Clinical data are from a controlled study and have been published in a peer‑reviewed scientific journal. They are provided for scientific and informational purposes only, not for advertising or promotion. The device has not been approved by any regulatory authority.